Searched for
BREAST CANCER DRUG PRICES
India needs five-year policy to make precision cancer care afforable, says expertIndia needs a five-year roadmap to expand access to genomic testing and targeted cancer therapies for lower-income patients, oncologist Dr ...- Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in IndiaNovartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, d...
- FDA Panel votes in favor of a $949 Cancer detecting blood test, but is Galleri ready for approval?Cancer cells can leave tiny fragments of DNA in the bloodstream. According to USA Today, Galleri studies chemical patterns found on these f...
- Lord’s Mark advances AI breast cancer screening towards clinical trialsIn a groundbreaking collaboration with C-MET, Lord's Mark Industries Limited is making strides in breast cancer screening technology. Utili...
- Cancer Weekly Horoscope (September 26-October 2, 2026): Your Biggest Strength This Week May Be Knowing When Not to ReactThis week, Cancer individuals may find their emotions running high, leading to potential hurdles in relationships and decision-making. It's...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- AI-based drug developer Basecamp valued at $800 million after $140 million funding roundThe oversubscribed round was led by S32, with participation from Nvidia, Anthropic's Anthology Fund, Catalio Capital Management, the NATO I...
- Cancer ♋ October 2026 Horoscope, Monthly Predictions: Major Changes Could Open New Doors In Career And LoveCancer individuals can expect significant changes in personal, professional, and financial aspects during October 2026. The first half enco...
- 'Inflated medicine prices are daylight robbery': SC pulls up pharma companies over huge MRP-PTR gapSupreme Court on Tuesday questioned the wide gap between the price to retailer and MRP of some cancer medicines, calling inflated pricing a...
- Global Market: European shares rise as oil slide boosts risk appetiteEuropean shares rose as technology stocks led gains and falling oil prices eased inflation concerns. The STOXX 600 advanced 0.56%, while in...
- Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar PebrilzoBiocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, ...
- Colorectal cancer is rising in adults under 50 and is now their leading cancer killer; warning signs and risk factors younger people should knowColorectal cancer has now emerged as the top cause of cancer mortality among Americans below fifty years old. This trend starkly contrasts ...
- Dr. Reddy's launches nivolumab biosimilar in IndiaDr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to...
- Fake Cancer Drug Racket Busted: A man was selling counterfeit medicines to 100 hospitals across Bengaluru and other statesA major fake cancer drug racket has been busted in Karnataka, with investigators alleging that a licensed pharmacist supplied counterfeit m...
- Manipal Hospitals scouts for acquisitions in Andhra, Keralam, Delhi-NCR; bets on AI-led healthcareManipal Health Enterprises plans significant expansion across several Indian states. The company is adopting a digital-physical healthcare ...
- AstraZeneca's breast cancer drug fails in late-stage trialAstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement whe...
- Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely sellerBiocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...
- Government panel plans to retain rule allowing doorstep drug deliveryA government sub-committee has decided to uphold the 2020 rule for doorstep delivery of medicines, recognizing its critical importance for ...
- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
Load More
